Bringing Oncology Innovation Closer to Patients | Cencora

The pace of oncology innovation continues to accelerate. In its 2025 Oncology Center of Excellence annual report, the FDA reported 70 oncology therapeutic product approvals, including 17 new molecular entities or biological license applications and approvals across pediatric cancer treatments, international review pathways and expanded access requests.

For patients, that progress represents new hope. For the healthcare system, it also raises a practical question: how do we make sure innovation reaches patients in the places where they receive care?

That question is especially important as more cancer care moves into community settings. Today, more than half of oncology care is delivered in community practices, where patients can often receive treatment closer to home, near their families, support systems and daily lives. For many patients, that proximity matters. But delivering advanced oncology care closer to home requires community practices to manage the same level of clinical, logistical and financial complexity that historically may have been concentrated in larger academic centers.

Access to advanced therapies is not only about whether a product is approved or available in the market. It is also about whether the systems around that therapy can support delivery safely, reliably and efficiently.